Association of CDX2 haplogenotype with risk of reflux
esophagitis, Barrett´s esophagus, and esophageal adenocarcinoma
development

a 2023

Association of CDX2 haplogenotype with risk of reflux esophagitis, Barrett´s esophagus, and esophageal adenocarcinoma development

BOŘILOVÁ LINHARTOVÁ, Petra, Natálie MLČŮCHOVÁ, Michaela CVANOVÁ, Zdeněk PAVLOVSKÝ, Miroslava CHOVANCOVÁ et. al.

Basic information

Original name

Association of CDX2 haplogenotype with risk of reflux esophagitis, Barrett´s esophagus, and esophageal adenocarcinoma development

Authors

BOŘILOVÁ LINHARTOVÁ, Petra (203 Czech Republic, guarantor, belonging to the institution), Natálie MLČŮCHOVÁ (203 Czech Republic), Michaela CVANOVÁ (203 Czech Republic), Zdeněk PAVLOVSKÝ (203 Czech Republic), Miroslava CHOVANCOVÁ (203 Czech Republic), Jiří DOLINA (203 Czech Republic), Lumír KUNOVSKÝ (203 Czech Republic), Radek KROUPA (203 Czech Republic), Lydie IZAKOVIČOVÁ HOLLÁ (203 Czech Republic), Ondřej URBAN, Tomáš HARUŠTIAK and Zdeněk KALA (203 Czech Republic)

Edition

Cancer World congress, Palermo 2023, 2023

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

10608 Biochemistry and molecular biology

Country of publisher

Italy

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14310/23:00131174

Organization unit

Faculty of Science

Keywords in English

CDX2; gastroesophageal reflux disease; esophagitis; markers

Změněno: 7/7/2023 10:39, Mgr. Terezie Slámová

Abstract

V originále

Introduction: Gastroesophageal reflux disease (GERD) can lead to reflux esophagitis (RE), Barrett’s esophagus (BE), and esophageal adenocarcinoma (EAC) development. CDX2 serves as a diagnostic marker for BE and EAC. Objective: Here, we present a genetic association study focused on CDX2 gene variability in Central European patients with GERD. Methods: In 376 endoscopically and histopathologically examined subjects: 279 cases (144 RE, 88 BE, 47 EAC) and 97 controls with nonerosive reflux disease, NERD), genomic DNA was analyzed for 2 polymorphisms in CDX2 (rs3812863, rs4769585). In a subgroup of cases (n=35), CDX2 was immunohistochemically examined in paired pathological and adjacent tissues of esophagus. Results: The distribution of allele frequencies of both CDX2 (rs3812863, rs4769585) polymorphisms differed between cases and controls, the CC genotype (rs4769585) was associated with risk of RE, BE, and EAC development (p≤0.05). The CDX2 AA/CC haplogenotype was found more frequent in cases than in controls (p<0.01). CDX2 protein was found in all BE (n=19) and EAC tissues (n=6), as well as in 3 RE tissues and in 2 esophageal tissue adjacent to lesions (n=35). Conclusion: The CDX2 is a specific tissue marker for BE and EAC diagnosis; variability in the CDX2 gene affects the risk of GERD development.

Links

LM2018121, research and development project

Name: Výzkumná infrastruktura RECETOX (Acronym: RECETOX RI)

Investor: Ministry of Education, Youth and Sports of the CR, RECETOX RI

NU20-03-00126, research and development project

Name: Hostitelský mikrobiom ve vztahu k rozvoji Barrettova jícnu a adenokarcinomu jícnu

Investor: Ministry of Health of the CR, Host microbiome in relation to Barrett ́s esophagus and esophageal adenocarcinoma development, Subprogram 1 - standard

Citovat

BOŘILOVÁ LINHARTOVÁ, Petra, Natálie MLČŮCHOVÁ, Michaela CVANOVÁ, Zdeněk PAVLOVSKÝ, Miroslava CHOVANCOVÁ, Jiří DOLINA, Lumír KUNOVSKÝ, Radek KROUPA, Lydie IZAKOVIČOVÁ HOLLÁ, Ondřej URBAN, Tomáš HARUŠTIAK and Zdeněk KALA. Association of CDX2 haplogenotype with risk of reflux esophagitis, Barrett´s esophagus, and esophageal adenocarcinoma development. In Cancer World congress, Palermo 2023. 2023.

@proceedings{2296500,
   author = {Bořilová Linhartová, Petra and Mlčůchová, Natálie and Cvanová, Michaela and Pavlovský, Zdeněk and Chovancová, Miroslava and Dolina, Jiří and Kunovský, Lumír and Kroupa, Radek and Izakovičová Hollá, Lydie and Urban, Ondřej and Haruštiak, Tomáš and Kala, Zdeněk},
   booktitle = {Cancer World congress, Palermo 2023},
   keywords = {CDX2; gastroesophageal reflux disease; esophagitis; markers},
   language = {eng},
   title = {Association of CDX2 haplogenotype with risk of reflux esophagitis, Barrett´s esophagus, and esophageal adenocarcinoma development},
   year = {2023}
}

TY  - CONF
ID  - 2296500
AU  - Bořilová Linhartová, Petra - Mlčůchová, Natálie - Cvanová, Michaela - Pavlovský, Zdeněk - Chovancová, Miroslava - Dolina, Jiří - Kunovský, Lumír - Kroupa, Radek - Izakovičová Hollá, Lydie - Urban, Ondřej - Haruštiak, Tomáš - Kala, Zdeněk
PY  - 2023
TI  - Association of CDX2 haplogenotype with risk of reflux esophagitis, Barrett´s esophagus, and esophageal adenocarcinoma development
KW  - CDX2
KW  - gastroesophageal reflux disease
KW  - esophagitis
KW  - markers
N2  - Introduction: Gastroesophageal reflux disease (GERD) can lead to reflux esophagitis (RE), Barrett’s esophagus (BE), and esophageal adenocarcinoma (EAC) development. CDX2 serves as a diagnostic marker for BE and EAC. Objective: Here, we present a genetic association study focused on CDX2 gene variability in Central European patients with GERD. Methods: In 376 endoscopically and histopathologically examined subjects: 279 cases (144 RE, 88 BE, 47 EAC) and 97 controls with nonerosive reflux disease, NERD), genomic DNA was analyzed for 2 polymorphisms in CDX2 (rs3812863, rs4769585). In a subgroup of cases (n=35), CDX2 was immunohistochemically examined in paired pathological and adjacent tissues of esophagus. Results: The distribution of allele frequencies of both CDX2 (rs3812863, rs4769585) polymorphisms differed between cases and controls, the CC genotype (rs4769585) was associated with risk of RE, BE, and EAC development (p≤0.05). The CDX2 AA/CC haplogenotype was found more frequent in cases than in controls (p<0.01). CDX2 protein was found in all BE (n=19) and EAC tissues (n=6), as well as in 3 RE tissues and in 2 esophageal tissue adjacent to lesions (n=35). Conclusion: The CDX2 is a specific tissue marker for BE and EAC diagnosis; variability in the CDX2 gene affects the risk of GERD development.
ER  -

Detailed Information on Publication Record